Alkermes plc
NASDAQ: ALKS
$27.70
-$0.21 (-0.8%)
Closing Price on November 21, 2024
ALKS Articles
The top analyst upgrades, downgrades and initiations seen on Friday included Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber Technologies and Vonage.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alkermes, Alphabet, Apple, ConocoPhillips, FireEye, Lyft, McDonald's, Royal Bank of Scotland, Seagate Technology and...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
Published:
Last Updated:
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western Digital.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Published:
Last Updated:
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Published:
Last Updated:
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Alkermes, ArQule, Bluebird Bio, Cognizant Technology Solutions, Ecolab, KLA-Tencor, Pandora Media, Verisk Analytics...
Published:
Last Updated:
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated:
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66 and United Rentals.
Published:
Last Updated:
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Cheniere Energy, Consolidated Edison, Foot Locker, Shopify, Tesla, Veeco Instruments and Zoetis.
Published:
Last Updated: